Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1977 Feb 12;1(6058):422–425. doi: 10.1136/bmj.1.6058.422

Why hypertensive patients vary in their response to oral debrisoquine.

J H Silas, M S Lennard, G T Tucker, A J Smith, S L Malcolm, T R Marten
PMCID: PMC1604845  PMID: 837136

Abstract

The relation between dose, systemic availability, and response to oral debrisoquine was studied in 13 hypertensive patients receiving no other treatment. In 11 who received the same daily dose (40 mg) the fall in mean standing systolic blood pressure varied between 0-3 and 44-4 mm Hg. There was a ninefold difference in the daily urinary excretion and pre-dose plasma concentration of unchanged drug but an inverse correlation between daily urinary excretion of debrisoquine and its 4-hydroxy metabolite (r= -0-86), suggesting that a low recovery of debrisoquine occurs because of extensive metabolism. There was a significant correlation between the fall in standing systolic blood pressure and the mean daily urinary excretion (r= +0-82) and pre-dose plasma concentration (r= +0-82) of unchanged debrisoquine. In contrast, there was a significant inverse correlation between the urinary recovery of the metabolite and the fall in blood pressure (r= -0-82). The availability of debrisoquine is the major determinant of response to this drug. In the absence of side effects a poor response may be an indication to increase the daily dose rather than add another hypotensive agent.

Full text

PDF
422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J. G., Brown A. N., Marten T. R. Metabolism of debrisoquine sulphate in rat, dog and man. Xenobiotica. 1976 Jul;6(7):405–409. doi: 10.3109/00498257609151653. [DOI] [PubMed] [Google Scholar]
  2. Allen J. G., East P. B., Francis R. J., Haigh J. L. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man. Drug Metab Dispos. 1975 Sep-Oct;3(5):332–337. [PubMed] [Google Scholar]
  3. Angelo M., Dring L. G., Lancaster R., Smith R. L. The metabolism of debrisoquine in rat and man. Biochem Soc Trans. 1976;4(4):704–706. doi: 10.1042/bst0040704. [DOI] [PubMed] [Google Scholar]
  4. Bühler F. R., Laragh J. H., Baer L., Vaughan E. D., Jr, Brunner H. R. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972 Dec 14;287(24):1209–1214. doi: 10.1056/NEJM197212142872401. [DOI] [PubMed] [Google Scholar]
  5. Dustan H. P., Tarazi R. C., Bravo E. L. Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl J Med. 1972 Apr 20;286(16):861–866. doi: 10.1056/NEJM197204202861603. [DOI] [PubMed] [Google Scholar]
  6. Kitchin A. H., Turner R. W. Studies on debrisoquine sulphate. Br Med J. 1966 Sep 24;2(5516):728–731. doi: 10.1136/bmj.2.5516.728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lennard M. S., Silas J. H., Smith A. J., Tucker G. T. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr. 1977 Mar 11;133(1):161–166. doi: 10.1016/s0021-9673(00)89216-x. [DOI] [PubMed] [Google Scholar]
  8. Louis W. J., Doyle A. E., Anavekar S. Plasma norepinephrine levels in essential hyoertension. N Engl J Med. 1973 Mar 22;288(12):599–601. doi: 10.1056/NEJM197303222881203. [DOI] [PubMed] [Google Scholar]
  9. Malcolm S. L., Marten T. R. Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry. Anal Chem. 1976 May;48(6):807–809. doi: 10.1021/ac60370a045. [DOI] [PubMed] [Google Scholar]
  10. Morgan T. O., Roberts R., Carney S. L., Louis W. J., Doyle A. E. Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol. 1975 Apr;2(2):159–164. doi: 10.1111/j.1365-2125.1975.tb01571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sandler G., Leishman A. W., Humberstone P. M. Guanethidine-resistant hypertension. Circulation. 1968 Sep;38(3):542–551. doi: 10.1161/01.cir.38.3.542. [DOI] [PubMed] [Google Scholar]
  12. Townshend M. M., Smith A. J. Factors influencing the urinary excretion of free catecholamines in man. Clin Sci. 1973 Mar;44(3):253–265. doi: 10.1042/cs0440253. [DOI] [PubMed] [Google Scholar]
  13. Weintraub M., Au W. Y., Lasagna L. Compliance as a determinant of serum digoxin concentration. JAMA. 1973 Apr 23;224(4):481–485. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES